



DEPARTMENT OF THE AIR FORCE
59TH MEDICAL WING (AETC)
JOINT BASE SAN ANTONIO - LACKLAND TEXAS



21 MAR 2017

MEMORANDUM FOR SGVT

ATTN: CAPT NICHOLAS SCALZITTI

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled Assessing How Hospital Readmissions are Affected by Obstructive Sleep Apnea Severity and Therapy Compliance presented at/published to Sleep 2017, Boston, MA, 3-7 June 2017 in accordance with MDWI 41-108, has been approved and assigned local file #17156.
2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.
4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

Linda Steel-Goodwin

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP) ; Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
4. Attach a copy of your abstract, paper, poster and other supporting documentation.
5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.
8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. **Note:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, *Presentation and Publication of Medical and Technical Papers*, for additional information.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP :

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

1. TO: CLINICAL RESEARCH	2. FROM: (Author's Name, Rank, Grade, Office Symbol) Nicholas Scalzitti, Capt, O-3, SGVT	3. GME/GHSE STUDENT: <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	4. PROTOCOL NUMBER: 414912 (BAMC IRB)
--------------------------	---	---	--

5. PROTOCOL TITLE: (**NOTE:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.)
The Relationship Between Obstructive Sleep Apnea and Hospital Readmission

6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:
Assessing how hospital readmissions are affected by obstructive sleep apnea severity and therapy compliance.

7. FUNDING RECEIVED FOR THIS STUDY? YES NO FUNDING SOURCE:

8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: YES NO

9. IS THIS MATERIAL CLASSIFIED? YES NO

10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? YES NO **NOTE:** If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.

11. MATERIAL IS FOR: DOMESTIC RELEASE FOREIGN RELEASE
CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.

11a. PUBLICATION/JOURNAL (List intended publication/journal.)

11b. PUBLISHED ABSTRACT (List intended journal.)

11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)
Sleep 2017, Boston, MA, June 3-7, 2017

11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)

11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)

12. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC
NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).

DATE 3/17/2017	
-------------------	--

13. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email) Scalzitti, Nicholas, J; nicholas.j.scalzitti.mil@mail.mil	14. DUTY PHONE/PAGER NUMBER 210-292-6929/ 210-594-4099
---	---

15. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.

LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP/OFFICE SYMBOL	INSTITUTION (If not 59 MDW)
a. Primary/Corresponding Author Scalzitti, Nicholas	Capt/O-3	59th TRS/ 59MDW/ SGVT	
b. Nielsen, Skyler W	Capt/O-3	59 CSPS	
c. Dion, Gregory R	MAJ/O-4	US Army/Otolaryngology Department	BAMC
d. Brock, Matthew S	Maj/O-4	59MDW/Sleep and Neurology clinics	
e. O'Connor, Peter D	LtCol/O-5	US Army/Otolaryngology Department	BAMC
f.			

I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

16. AUTHOR'S PRINTED NAME, RANK, GRADE Nicholas Scalzitti, Capt, O-3	17. AUTHOR'S SIGNATURE SCALZITTI,NICHOLAS J.13007497 <small>Digitally signed by SCALZITTI,NICHOLAS J.13007497 (DN: cn=SCALZITTI,NICHOLAS J.13007497, o=USAF, ou=USAF, email=SCALZITTI,NICHOLAS J.13007497@usaf.af.mil, c=US)</small>	18. DATE 3/17/2017
---	--	-----------------------

19. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE Shana Hansen, LtCol, Associate Program Director, Sleep Medicine	20. APPROVING AUTHORITY'S SIGNATURE HANSEN SHANA LEE.1232764089 <small>Digitally signed by HANSEN SHANA LEE.1232764089 (DN: cn=HANSEN SHANA LEE.1232764089, o=USAF, ou=USAF, email=HANSEN SHANA LEE.1232764089@usaf.af.mil, c=US)</small>	21. DATE 3/20/2017
--	---	-----------------------

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

1st ENDORSEMENT (59 MDW/SGVU Use Only)

TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions.	22. DATE RECEIVED March 20, 2017	23. ASSIGNED PROCESSING REQUEST FILE NUMBER 17156
--	-------------------------------------	--

24. DATE REVIEWED March 21, 2017	25. DATE FORWARDED TO 502 ISG/JAC
-------------------------------------	-----------------------------------

26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: NO YES If yes, give date. _____ N/A

27. COMMENTS APPROVED DISAPPROVED

Poster presentation of IRB approved study. Appropriate disclaimers included. Approved

28. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Kevin Kupferer/GS13/Human Research Subject Protection Expert	29. REVIEWER SIGNATURE KUPFERER KEVIN R. 1086667270 <small>Digitally signed by KUPFERER KEVIN R. 1086667270 DN: cn=KUPFERER KEVIN R. 1086667270, o=59 MDW/CRD Date: 2017.03.21 10:22:08 -0500</small>	30. DATE March 21, 2017
---	---	----------------------------

2nd ENDORSEMENT (502 ISG/JAC Use Only)

31. DATE RECEIVED	32. DATE FORWARDED TO 59 MDW/PA
-------------------	---------------------------------

33. COMMENTS APPROVED (In compliance with security and policy review directives.) DISAPPROVED

34. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	35. REVIEWER SIGNATURE	36. DATE
---	------------------------	----------

3rd ENDORSEMENT (59 MDW/PA Use Only)

37. DATE RECEIVED March 21, 2017	38. DATE FORWARDED TO 59 MDW/SGVU March 21, 2017
-------------------------------------	---

39. COMMENTS APPROVED (In compliance with security and policy review directives.) DISAPPROVED

40. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Kevin Inuma, SSgt/E-5, 59 MDW Public Affairs	41. REVIEWER SIGNATURE IINUMA KEVIN MITSUGU.1296227 613 <small>Digitally signed by IINUMA KEVIN MITSUGU.1296227 DN: cn=IINUMA KEVIN MITSUGU.1296227, o=59 MDW/PA Date: 2017.03.21 11:53:51 -0500</small>	42. DATE March 21, 2017
---	---	----------------------------

4th ENDORSEMENT (59 MDW/SGVU Use Only)

43. DATE RECEIVED	44. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> COULD NOT BE REACHED <input type="checkbox"/> LEFT MESSAGE
-------------------	--

45. COMMENTS APPROVED DISAPPROVED

46. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	47. REVIEWER SIGNATURE	48. DATE
---	------------------------	----------

Title: Assessing How Hospital Readmissions are Affected by Obstructive Sleep Apnea Severity and Therapy Compliance

Authors and Institutions: Nicholas Scalzitti, MD^{1,2}; Skyler Nielsen, DO²; Gregory Dion, MD²; Matthew Brock, MD¹; Peter O'Connor, MD^{1,2}

¹Department of Sleep Medicine, San Antonio Uniformed Services Health Education Consortium, San Antonio, TX; ²Department of Otolaryngology-Head and Neck Surgery, San Antonio Uniformed Services Health Education Consortium, San Antonio, TX

Introduction:

Hospital readmissions are an important quality metric reported to the Centers for Medicare and Medicaid Services. Previous work from our group found that the presence of obstructive sleep apnea (OSA) correlates with increased risk of hospital readmission within 30 days. This project seeks to characterize the relationship between readmissions and the severity and treatment of OSA. A better understanding of this relationship could potentially be utilized to develop preventative measures and reduce readmission.

Methods:

A retrospective review of all hospital discharges over a 24-month period (August 2011–July 2013) for a Department of Defense tertiary care hospital was conducted. Of 22,261 unique discharges, 5,299 patients had OSA based on ICD-9 codes. Of these patients with OSA, 565 were readmitted. From this group, 125 patients were randomly selected for further review. An additional age and gender-matched 125 patients with OSA that were not readmitted were selected for comparison. The groups were compared with parametric and non-parametric tests.

Results:

For the 250 patients, ages ranged from 18 to 96 years (mean 63.2). Polysomnography data was found for 152 patients (77 readmitted and 75 non-readmitted). Based on the available polysomnography data, 67 readmitted and 66 non-readmitted patients met criteria for OSA. Apnea-hypopnea index ranged from 0 to 110.7 (mean 24.1) and 0.2 to 109 (mean 27.2) for the readmitted and non-readmitted groups respectively ($p=0.48$). Similarly, lowest oxygen saturations averaging 83.9 and 84.1 ($p=0.88$), and body mass index averaging 31.3 and 31.6 ($p=0.67$) were not statistically different. Inpatient (27.2% vs. 26.4%) and outpatient (38.4% vs. 37.6%) treatment rates were not different. Length of hospital stay (5.1 vs. 3.6 days in readmitted vs. non-readmitted) differed between the 2 groups ($p=0.007$).

Conclusion:

While OSA is an independent risk factor for hospital readmission, OSA severity and treatment compliance did not differ between readmitted and non-readmitted patients. Of the factors studied, only

length of stay during the original admission correlated with higher likelihood of readmission. Additional studies on hospital readmission in OSA patients are needed to determine if readmission rates can be improved through better recognition and treatment of OSA.

Disclaimer:

The views expressed are those of the author(s)/presenter(s) and do not reflect the official views or policy of the Department of Defense or its Components.